Lung Cancer Clinical Trial

Immune and Genomic Markers in ALK+ NSCLC

Summary

The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)

View Full Description

Full Description

The purpose of this study is to establish a registry of clinical data and tumor specimens of patients with advanced ALK+ non-small lung cancer (NSCLC) (defined as NSCLC harboring an ALK gene rearrangement). This will allow in-depth, comprehensive genomic and immunophenotypic analyses of ALK+ tumors. Together with the clinical data, these biologic specimens will enable the conduct of basic and translational research to identify genomic and immunologic markers associated with clinical outcomes for ALK+ patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Cohort 1 - Alive Individuals

Men or women 18 years of age or the age of majority for their residential state of the United States, or older, at the time of consent.
Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to curative approach multi-modality (e.g., chemoradiation and/or surgery) treatment, or stage IV non-small cell lung cancer (NSCLC)
Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected in at least 15% of tumor cells.
Willingness to provide clinical and medical information to the study team as required.
Willingness to provide archival tumor tissue, if available. Patients may enroll even if no tumor tissue is available.
Ability to read, write and communicate in English.
Ability to sign a web-based informed consent form.

Cohort 2 - Deceased Individuals

Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older may be studied on a case by case basis. Inclusion will require availability of adequate archived tissue and release of tissue and records by next of kin, if available.

Exclusion Criteria:

Participants who are unwilling to provide informed consent.
Participants who are younger than 18 years of age.
Participants who are unable to comply with the study procedures.
Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
Participants who have previously enrolled to the study.

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT04881916

Recruitment Status:

Recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Massachusetts General Hospital Cancer Center
Boston Massachusetts, 02114, United States More Info
Jessica J Lin, MD
Contact
617-724-4000
[email protected]
Jessica J Lin, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

100

Study ID:

NCT04881916

Recruitment Status:

Recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider